Conatus Pharmaceuticals Inc. buy stratec
Zusammenfassung
Diese Einschätzung wurde am 04.03.19 mit einem Endkurs von 19,12 € beendet. Stark abwärts ging es für die BUY Einschätzung von stratec zu Conatus Pharmaceuticals Inc. mit einer Rendite von -61,31 %. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Conatus Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | -1,04 % | 2,22 % | 14,28 % | 15,46 % |
iShares Nasdaq 100 | -1,36 % | 3,21 % | 26,66 % | 53,27 % |
iShares Nikkei 225® | -0,04 % | -1,68 % | 5,94 % | 4,27 % |
iShares S&P 500 | -0,48 % | 2,16 % | 23,07 % | 45,28 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Conatus Pharmaceuticals Inc. diskutieren
Conatus, one of the most promising small cap NASH companies.
Conatus Pharmaceuticals (NASDAQ:CNAT) initiated with Outperform rating and $16 (208% upside) price target at Oppenheimer.
Conatus’s lead product candidate is emricasan, a first-in-class pan-caspase protease inhibitor designed to reduce the activity of human caspases. NASH has been associated with caspase activation. By reducing the activity of caspase, emricasan can potentially interrupt liver disease progression. And there is some compelling pre-clinical and clinical data to back this. Emricasan has already been studied in sixteen clinical trials and has shown promise. This was the reason Novartis entered into a collaboration agreement with Conatus in December 2016.